A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying [Yahoo! Finance]
Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
Company Research
Source: Yahoo! Finance
2 DENALI trial, FDA alignment on the Phase 3 ASPENOVA design, and a large insider share purchase. See our latest analysis for Zentalis Pharmaceuticals. The latest clinical milestones and insider buying have coincided with a sharp shift in sentiment, with a 7 day share price return of 172.99% and a 90 day share price return of 130.86%. However, the 3 year total shareholder return of an 85% decline shows longer term holders are still well under water, suggesting recent momentum is rebuilding from a much lower base. If this kind of oncology rebound catches your interest, it could be worth scanning other healthcare stocks that might be drawing attention for similar reasons. With the stock up very sharply in recent months yet still carrying an intrinsic discount estimate and trading below the average analyst price target, investors may reasonably ask whether there is still a buying opportunity here or whether the market is already pricing in future growth. On a P/S of 9x at a las
Show less
Read more
Impact Snapshot
Event Time:
ZNTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZNTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZNTL alerts
High impacting Zentalis Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ZNTL
News
- Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026GlobeNewswire
- Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell [Yahoo! Finance]Yahoo! Finance
- Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval [Seeking Alpha]Seeking Alpha
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ZNTL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target lowered by analysts at Morgan Stanley from $8.00 to $4.00. They now have an "equal weight" rating on the stock.MarketBeat
ZNTL
Earnings
- 11/10/25 - Beat
ZNTL
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- ZNTL's page on the SEC website